Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists
- 11 July 2006
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (16) , 4801-4804
Abstract
Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an ongoing program targeting CCR2 antagonists. Optimization of 11 leading to antagonists 26 and 37 is described. Antagonist 26 was shown to have good oral bioavailability in rats. Antagonist 37 had a CCR2 IC50 of 59 nM and excellent potency in a functional assay measuring inhibition of MCP-1 induced monocyte chemotaxis (IC50 of 41 nM).Keywords
This publication has 9 references indexed in Scilit:
- Chemokines: more than just road signsNature Reviews Immunology, 2006
- The CCR2 receptor as a therapeutic targetExpert Opinion on Therapeutic Patents, 2005
- MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein BJournal of Clinical Investigation, 1999
- Opportunities for novel therapeutic agents acting at chemokine receptorsDrug Discovery Today, 1999
- Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosisNature, 1998
- Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.Proceedings of the National Academy of Sciences, 1994
- Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugsCytokine, 1994
- Orally active, nonpeptide oxytocin antagonistsJournal of Medicinal Chemistry, 1992
- Spiropiperidines as high-affinity, selective .sigma. ligands.Journal of Medicinal Chemistry, 1992